205 related articles for article (PubMed ID: 32930551)
1. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
Parasrampuria S; Sen AP; Anderson GF
Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551
[TBL] [Abstract][Full Text] [Related]
2. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
4. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
5. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
6. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
Dusetzina SB; Huskamp HA; Qin X; Keating NL
JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
8. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
9. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
10. In-gap discounts in Medicare Part D and specialty drug use.
Jung J; Xu WY; Cheong C
Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
[TBL] [Abstract][Full Text] [Related]
11. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
Mishuk AU; Fasina I; Qian J
Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
[TBL] [Abstract][Full Text] [Related]
12. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
13. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
14. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
15. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
16. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
17. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11.
Trish E; Joyce G; Goldman DP
Health Aff (Millwood); 2014 Nov; 33(11):2018-24. PubMed ID: 25367998
[TBL] [Abstract][Full Text] [Related]
18. Out-of-Pocket Spending for Thumb Carpometacarpal Arthritis: Capitation Matters.
Billig JI; Lu YT; Kelley BP; Chung KC; Sears ED
Hand (N Y); 2021 Nov; 16(6):818-826. PubMed ID: 32088982
[No Abstract] [Full Text] [Related]
19. Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction.
Fendrick AM; Djatche L; Pulungan Z; Teigland C; Yang M; Lautsch D; Hilkert R; Mentz R
Am Heart J; 2022 Apr; 246():74-81. PubMed ID: 34774543
[TBL] [Abstract][Full Text] [Related]
20. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
